Pharmacology at work for cardio-oncology: Ranolazine to treat early cardiotoxicity induced by antitumor drugs

Journal of Pharmacology and Experimental Therapeutics

Volumn 346, Issue 3, 2013, Pages 343-349

  Minotti, Giorgio ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BRAIN NATRIURETIC PEPTIDE; DOXORUBICIN; RANOLAZINE; RAZOXANE; TROPONIN;

ACUTE TOXICITY; ANGINA PECTORIS; BREAST CANCER; CARDIOTOXICITY; CARDIOVASCULAR RISK; CHRONIC TOXICITY; CONSTIPATION; DIASTOLIC DYSFUNCTION; DIZZINESS; DRUG APPROVAL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EXPERIMENTAL DESIGN; HEART ARRHYTHMIA; HEART INFARCTION; HEART MUSCLE CONTRACTILITY; HUMAN; HYPOTENSION; IC 50; MALIGNANT NEOPLASTIC DISEASE; NAUSEA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; SIDE EFFECT;

ACETANILIDES; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; FEMALE; HEART DISEASES; HEART FAILURE, DIASTOLIC; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; PIPERAZINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; YOUNG ADULT;

EID: 84882336454     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.113.204057     Document Type: Review

References (54)

1. Altena R, de Haas EC, Nuver J, Brouwer CA, van den Berg MP, Smit AJ, Postma A, Sleijfer DT, and Gietema JA (2009) Evaluation of sub-acute changes in cardiac function after cisplatin-based combination chemotherapy for testicular cancer. Br J Cancer 100:1861-1866.
2. American Cancer Society (2012) Cancer Treatment and Survivorship Facts & Figures, American Cancer Society, Atlanta, GA.
3. Antzelevitch CT, Belardinelli L, Zygmunt AC, Burashnikov A, Di Diego JM, Fish JM, Cordeiro JM, and Thomas G (2004) Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 110: 904-910.
4. Armstrong GT, Kawashima T, Leisenring WM, Stovall M, Sklar CA, Robison LL, and Oeffinger KC (2012) Increasing risk of chronic health conditions in aging survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (Abstract). J Clin Oncol 30:9514A.
5. Barry E, Alvarez JA, Scully RE, Miller TL, and Lipshultz SE (2007) Anthracyclineinduced cardiotoxicity: course, pathophysiology, prevention and management. Expert Opin Pharmacother 8:1039-1058.
6. Belardinelli L, Shryock JC, and Fraser H (2006) Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine. Heart 92 (Suppl 4):iv6-iv14.
7. Beyder A, Strege PR, Reyes S, Bernard CE, Terzic A, Makielski J, Ackerman MJ, and Farrugia G (2012) Ranolazine decreases mechanosensitivity of the voltagegated sodium ion channel Na(v)1.5: a novel mechanism of drug action. Circulation 125:2698-2706.
8. Borlaug BA and Paulus WJ (2011) Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J 32:670-679.
9. Braunwald E (2008) Biomarkers in heart failure. N Engl J Med 358:2148-2159.
10. Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, Martinelli G, Veglia F, Fiorentini C, and Cipolla CM (2006) Prevention of high-dose chemotherapyinduced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 114:2474-2481.
11. Carver JR, Shapiro CL, Ng A, Jacobs L, Schwartz C, Virgo KS, Hagerty KL, Somerfield MR, and Vaughn DJ; ASCO Cancer Survivorship Expert Panel (2007)
12. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol 25: 3991-4008.
13. Dalen H, Thorstensen A, Aase SA, Ingul CB, Torp H, Vatten LJ, and Stoylen A (2010) Segmental and global longitudinal strain and strain rate based on echocardiography of 1266 healthy individuals: the HUNT study in Norway. Eur J Echocardiogr 11:176-183.
14. Figueredo VM, Pressman GS, Romero-Corral A, Murdock E, Holderbach P, and Morris DL (2011) Improvement in left ventricular systolic and diastolic performance during ranolazine treatment in patients with stable angina. J Cardiovasc Pharmacol Ther 16:168-172.
15. Ganey PE, Carter LS, Mueller RA, and Thurman RG (1991) Doxorubicin toxicity in perfused rat heart. Decreased cell death at low oxygen tension. Circ Res 68: 1610-1613.
16. Gianni L, Herman EH, Lipshultz SE, Minotti G, Sarvazyan N, and Sawyer DB (2008) Anthracycline cardiotoxicity: from bench to bedside. J Clin Oncol 26:3777-3784.
17. Hale SL, Shryock JC, Belardinelli L, Sweeney M, and Kloner RA (2008) Late sodium current inhibition as a new cardioprotective approach. J Mol Cell Cardiol 44: 954-967.
18. Hayashida W, van Eyll C, Rousseau MF, and Pouleur H (1994) Effects of ranolazine on left ventricular regional diastolic function in patients with ischemic heart disease. Cardiovasc Drugs Ther 8:741-747.
19. Hudson MM, Rai SN, Nunez C, Merchant TE, Marina NM, Zalamea N, Cox C, Phipps S, Pompeu R, and Rosenthal D (2007) Noninvasive evaluation of late anthracycline cardiac toxicity in childhood cancer survivors. J Clin Oncol 25:3635-3643.
20. Hwang H, Arcidi JM, Jr, Hale SL, Simkhovich BZ, Belardinelli L, Dhalla AK, Shryock JC, and Kloner RA (2009) Ranolazine as a cardioplegia additive improves recovery of diastolic function in isolated rat hearts. Circulation 120(Suppl)S16-S21.
21. Jerling M (2006) Clinical pharmacokinetics of ranolazine. Clin Pharmacokinet 45: 469-491.
22. Kamba T and McDonald DM (2007) Mecha nisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 96:1788-1795.
23. Lal H, Kolaja KL, and Force T (2013) Cancer genetics and the cardiotoxicity of the therapeutics. J Am Coll Cardiol 61:267-274.
24. Lovelock JD, Monasky MM, Jeong EM, Lardin HA, Liu H, Patel BG, Taglieri DM, Gu L, Kumar P, and Pokhrel N, et al. (2012) Ranolazine improves cardiac diastolic dysfunction through modulation of myofilament calcium sensitivity. Circ Res 110: 841-850.
25. Lyu YL, Kerrigan JE, Lin CP, Azarova AM, Tsai YC, Ban Y, and Liu LF (2007) Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res 67:8839-8846.
26. MacInnes A, Fairman DA, Binding P, Rhodes Ja, Wyatt MJ, Phelan A, Haddock PS, and Karran EH (2003) The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 93:e26-e32.
27. Maltsev VA and Undrovinas A (2008) Late sodium current in failing heart: friend or foe? Prog Biophys Mol Biol 96:421-451.
28. Marwick TH, Leano RL, Brown J, Sun JP, Hoffmann R, Lysyansky P, Becker M, and Thomas JD (2009) Myocardial strain measurement with 2-dimensional speckle-tracking echocardiography: definition of normal range. JACC Cardiovasc Imaging 2:80-84.
29. Matsumura H, Hara A, Hashizume H, Maruyama K, and Abiko Y (1998) Protective effects of ranolazine, a novel anti-ischemic drug, on the hydrogen peroxide-induced derangements in isolated, perfused rat heart: comparison with dichloroacetate. Jpn J Pharmacol 77:31-39.
30. Menna P, Paz OG, Chello M, Covino E, Salvatorelli E, and Minotti G (2012) Anthracycline cardiotoxicity. Expert Opin Drug Saf 11 (Suppl 1):S21-S36.
31. Menna P, Salvatorelli E, and Minotti G (2008) Cardiotoxicity of antitumor drugs. Chem Res Toxicol 21:978-989.
32. Minotti G, Menna P, Salvatorelli E, Cairo G, and Gianni L (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56:185-229.
33. Minotti G, Salvatorelli E, and Menna P (2010) Pharmacological foundations of cardiooncology. J Pharmacol Exp Ther 334:2-8.
34. Moss AJ, Zareba W, Schwarz KQ, Rosero S, McNitt S, and Robinson JL (2008) Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome. J Cardiovasc Electrophysiol 19: 1289-1293.
35. Mottram PM and Marwick TH (2005) Assessment of diastolic func tion: what the general cardiologist needs to know. Heart 91:681-695.
36. Mulrooney DA, Yeazel MW, Kawashima T, Mertens AC, Mitby P, Stovall M, Donaldson SS, Green DM, Sklar CA, and Robison LL , et al. (2009) Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 339:b4606.
37. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, Waggoner AD, Flachskampf FA, Pellikka PA, and Evangelista A (2009) Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 22:107-133.
38. Paulus WJ and van Ballegoij JJ (2010) Treatment of heart failure with normal ejection fraction: an inconvenient truth! J Am Coll Cardiol 55:526-537.
39. Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, and Giordano SH (2007) Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 25:3808-3815.
40. Sandri MT, Salvatici M, Cardinale D, Zorzino L, Passerini R, Lentati P, Leon M, Civelli M, Martinelli G, and Cipolla CM (2005) N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunctio n? Clin Chem 51:1405-1410.
41. Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Tan TC, Cohen V, Banchs J, Carver JR, and Wiegers SE, et al. (2012) Assessment of echocardiography and bioma rkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging 5:596-603.
42. Schmidinger M, Zielinski CC, Vogl UM, Bojic A, Bojic M, Schukro C, Ruhsam M, Hejna M, and Schmidinger H (2008) Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 26:5204-5212.
43. Schuchter LM, Hensley ML, Meropol NJ, and Winer EP (2002) American Society of Clinical Oncology Chemotherapy and Radiotherapy Expert Panel. 2002 Update of recommendations for t he use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 20:2895-2903.
44. Scirica BM, Morrow DA, Hod H, Murphy SA, Belardinelli L, Hedgepeth CM, Molhoek P, Verheugt FW, Gersh BJ, And McCabe CH, et al. (2007) Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non S T-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Ci rculation 116:1647-1652.
45. Sossalla S, Wagner S, Rasenack EC, Ruff H, Weber SL, Schöndube FA, Tirilomis T, Tenderich G, Hasenfuss G, and Belardinelli L, et al. (2008) Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts-role of late sodium current and intracellular ion accumulation. J Mol Cell Cardiol 45: 32-43.
46. Stone PH (2008) Ranolazine: new paradigm for management of myocardial ischemia, myocardial dysfunction, and arrhythmias. Cardiol Clin 26:603-614.
47. Suter TM and Ewer MS (2013) Cancer drugs and the h eart: importance and management. Eur Heart J 34:1102-1111.
48. Swain SM, Whaley FS, and Ewer MS (2003) Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97: 2869-2879.
49. Swain SM, Whaley FS, Gerber MC, Weisberg S, York M, Spicer D, Jones SE, Wadler S, Desai A, and Vogel C, et al. (1997) Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 15: 1318-1332.
50. Swerdlow AJ, Higgins CD, Smith P, Cunningham D, Hancock BW, Horwich A, Hoskin PJ, Lister A, Radford JA, and Rohatiner AZS, et al. (2007) Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst 99:206-214.
51. Tassan-Mangina S, Codorean D, Metivier M, Costa B, Himberlin C, Jouannaud C, Blaise AM, Elaerts J, and Nazeyrollas P (2006) Tissue Doppler imaging and conventional echocardiography after anthracycline treatment in adults: early and late alterat ions of left ventricular function during a prospective study. Eur J Echocardiogr 7:141-146.
52. Wilde S, Jetter A, Rietbrock S, Kasel D, Engert A, Josting A, Klimm B, Hempel G, Reif S, and Jaehde U, et al. (2007) Population pharmacokinetics of the BEACOPP polychemotherapy regimen in Hodgkin?s lymphoma and its effect on myelotoxicity. Clin Pharmacokinet 46:319-333.
53. Xi Y, Wu G, Yang L, Han K, Du Y, Wang T, Lei X, Bai X, and Ma A (2009) Increased late sodium currents are related to transcription of neuronal isoforms in a pressure- overload model. Eur J Heart Fail 11:749-757.
54. Zhang S, Liu X, Bawa-Khalfe T, Lu LS, Lyu YL, Liu LF, and Yeh ET (2012) Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med 18: 1639-1642.